# Pliant Therapeutics, Inc.: overview PLRX · Nasdaq · CIK 1746473 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/plrx.md) · [Financials](/companies/plrx/financials.md) · [Filings](/companies/plrx/filings.md) · [Insiders](/companies/plrx/insiders.md) Latest reported revenue: [$0](/filings/0001746473-26-000037.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001746473-26-000037). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001746473-24-000171.md) | [0.0 d](/filings/0001746473-26-000037.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.95)](/filings/0001746473-25-000175.md) | not reported | [(0.92)](/filings/0001746473-26-000090.md) | [(0.71)](/filings/0001746473-26-000113.md) | [(0.43)](/filings/0001746473-25-000175.md) | not reported | [(0.32)](/filings/0001746473-26-000090.md) | [(0.36)](/filings/0001746473-26-000113.md) | | Free cash flow | $m | [(33.2) d](/filings/0001746473-25-000175.md) | [(47.9) d](/filings/0001746473-26-000037.md) | [(49.1)](/filings/0001746473-26-000090.md) | [(40.7) d](/filings/0001746473-26-000113.md) | [(21.1) d](/filings/0001746473-25-000175.md) | [(17.8) d](/filings/0001746473-26-000037.md) | [(19.2)](/filings/0001746473-26-000090.md) | [(12.8) d](/filings/0001746473-26-000113.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.6](/filings/0001746473-24-000043.md) | [9.7](/filings/0001746473-25-000054.md) | [1.6](/filings/0001746473-25-000054.md) | [0.0](/filings/0001746473-26-000037.md) | [0.0](/filings/0001746473-26-000037.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1288.1%)](/filings/0001746473-24-000043.md) | [(1313.4%)](/filings/0001746473-25-000054.md) | [(11654.7%)](/filings/0001746473-25-000054.md) | not reported | not reported | | Net margin | % | [(1284.5%)](/filings/0001746473-24-000043.md) | [(1273.3%)](/filings/0001746473-25-000054.md) | [(10211.1%)](/filings/0001746473-25-000054.md) | not reported | not reported | | Diluted EPS | $ per share | [(2.71)](/filings/0001746473-24-000043.md) | [(2.94)](/filings/0001746473-25-000054.md) | [(2.75)](/filings/0001746473-25-000054.md) | [(3.47)](/filings/0001746473-26-000037.md) | [(2.43)](/filings/0001746473-26-000037.md) | | Free cash flow | $m | [(77.4)](/filings/0001746473-24-000043.md) | [(96.4)](/filings/0001746473-25-000054.md) | [(117)](/filings/0001746473-25-000054.md) | [(159)](/filings/0001746473-26-000037.md) | [(129)](/filings/0001746473-26-000037.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/plrx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TANG CAPITAL MANAGEMENT LLC](/funds/1232621.md) | 2026-06-30 | $7.0m | 6,141,261 | | Reduced −1,871 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $6.3m | 5,509,724 | | Added +2,924,598 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.8m | 2,440,351 | | Added +97,250 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $2.6m | 2,262,832 | | Added +9,694 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $2.4m | 2,142,226 | | Reduced −1,084,373 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $2.3m | 2,049,874 | | Added +197,032 | | [Monaco Asset Management SAM](/funds/1803593.md) | 2026-06-30 | $2.2m | 1,938,747 | | Unchanged | | [Lynx1 Capital Management LP](/funds/1910456.md) | 2026-06-30 | $2.0m | 1,798,070 | | New +1,798,070 | | [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $1.8m | 1,546,137 | | Unchanged | | [Prosight Management, LP](/funds/1617201.md) | 2026-06-30 | $1.6m | 1,370,233 | | Reduced −297,367 | ## Recent filings [All 435 filings](/companies/plrx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 20:10 ET | [8-K](/filings/0001746473-26-000115.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001746473-26-000115 | | 2026-08-11 | 20:08 ET | [10-Q](/filings/0001746473-26-000113.md) | Quarterly report, period 2026-06-30 | 0001746473-26-000113 | | 2026-07-13 | 20:25 ET | [8-K](/filings/0001746473-26-000107.md) | 5.02 Departure or appointment of officers or directors | 0001746473-26-000107 | | 2026-06-11 | 20:52 ET | [8-K](/filings/0001746473-26-000092.md) | 5.07 Shareholder vote results | 0001746473-26-000092 | | 2026-05-11 | 20:10 ET | [10-Q](/filings/0001746473-26-000090.md) | Quarterly report, period 2026-03-31 | 0001746473-26-000090 | | 2026-05-11 | 20:07 ET | [8-K](/filings/0001746473-26-000088.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001746473-26-000088 | | 2026-04-22 | 20:30 ET | [DEF 14A](/filings/0001746473-26-000076.md) | Proxy statement, period 2026-06-11 | 0001746473-26-000076 | | 2026-04-17 | 20:30 ET | [8-K](/filings/0001746473-26-000050.md) | 5.02 Departure or appointment of officers or directors | 0001746473-26-000050 | | 2026-03-30 | 21:38 ET | [8-K](/filings/0001746473-26-000046.md) | 8.01 Other events | 0001746473-26-000046 | | 2026-03-11 | 20:31 ET | [8-K](/filings/0001746473-26-000039.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001746473-26-000039 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001746473-26-000037.md), filed Mar 11, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1746473 - Tickers: PLRX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.